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MicroRNAs (miRNAs) are regulatory molecules able to influence all aspects of the biology of a cell. They have been associated with
diseases such as cancer, viral infections, and autoimmune diseases, and in recent years, they also emerged as important regulators
of immune responses. MiR-146a in particular is rapidly gaining importance as a modulator of diﬀerentiation and function of
cells of the innate as well as adaptive immunity. Given its importance in regulating key cellular functions, it is not surprising that
miR-146a expression was also found dysregulated in diﬀerent types of tumors. In this paper, we summarize recent progress in
understanding the role of miR-146a in innate and adaptive immune responses, as well as in disease.
1. Introduction
MicroRNAs (miRNAs) represent a pervasive feature of all
cells, as they regulate large fractions of the cell’s tran-
scriptome. So far, 672 mouse miRNAs and 1048 human
miRNAs have been described in the miRBase database
(http://www.mirbase.org/, release Sept. 2010) with each
miRNA potentially regulating the expression of hundreds of
target genes, highlighting the extent of this form of regulation
[1]. Whereas some miRNAs are widely expressed, others
exhibit only limited developmental stage-, tissue-, or cell
type-specific patterns [2]. Similar to any other mammalian
cell type, cells of the immune system rely on miRNAs to
regulate lineage commitment, proliferation, migration, and
diﬀerentiation. Inmost cases, these activities are orchestrated
by both ubiquitously expressed and cell type-specific miRNA
species [3–7]. The importance of miRNAs in regulating
diﬀerentiation and function of immune cells is underlined
by the phenotypical perturbations that occur when miRNA
expression is altered. Given the emerging roles of miRNAs in
modulating immune responses, it is likely that any dysreg-
ulation of miRNA expression may contribute to the patho-
genesis of autoimmune diseases, chronic inflammation, and
malignancies. Indeed, several human diseases have now
been associated with dysregulated miRNA expression, and
miRNAs have been shown to function both as oncogenes and
tumor suppressor genes [8, 9]. MiR-146a has been recently
shown to be an important modulator of diﬀerentiation and
function of cells of innate as well as adaptive immunity.
Here, we summarize recent progress in understanding the
role of miR-146a in immune responses and in disease (see
also Table 1).
2. What Are MicroRNAs?
MiRNAs are small (20–25 nucleotides), noncoding RNA
molecules involved in posttranscriptional gene regulation.
They derive from primary transcripts (pri-miRNA) that
are processed into hairpin precursors (pre-miRNAs) within
the nucleus of the cell by the Microprocessor complex,
which includes the RNAseIII enzyme Drosha. Pre-miRNAs
are translocated into the cytoplasm and processed by Dicer
into their mature form (for a recent review see [25]). An
exception to this rule is represented by the less abundant
“mirtrons”, that bypass Drosha and are processed only by
Dicer [26]. Mature miRNAs loaded onto the RNA-induced
silencing complex (RISC) recognize sites located mostly
in the 3′ untranslated region (3′ UTR) of target mRNAs
through canonical base-pairing between the seed sequence
of the miRNA (nucleotides 2–8 at its 5′ end) and its
complementary sequence in the target mRNA. This leads to
a block in translation with or without destabilization and
degradation of the targeted mRNA. MiRNAs modulate a
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Table 1: Summary of the described roles for miR-146a in immune responses and disease, with indicated references and known targets.
Ref. Expression/Function Targets
Mouse
[5] Diﬀerential expression in Th1/Th2 cells
[10] Impaired Treg function in mice lacking miR-146a STAT1
[11] Provided protection from bacteria induced epithelial damage in neonates IRAK1
Human
[12] Attenuated TLR4 signaling in monocytes IRAK1, TRAF6
[13] Regulated activation induced cell death and IL-2 expression in Jurkat T cells FADD
[14] Contributed to the establishment of endotoxin tolerance in monocytes IRAK1, TRAF6
[15] Desensitized Langerhans cells to inappropriate TLR signaling
[16] Negatively regulated inflammatory response in lung epithelial cells
[17] Controlled megakaryopoiesis CXCR4
[18] Reduced migration and invasion capacity of breast cancer cells IRAK1, TRAF6
[19] Promoted cell proliferation in cervical cancer
[20] Tumor suppressor in hormone-refractory prostate cancer ROCK1
[21] Suppressed invasion of pancreatic cancer cells EGFR, IRAK1
[22] SNP in pre-miR-146a predisposes to papillary thyroid carcinoma
Viruses
[23] Promoted VSV replication in macrophages IRAK1, IRAK2, TRAF6
[24] EBV-encoded LMP1 induced cellular miR-146a expression
broad range of gene expression patterns during development
and homeostasis, as well as in pathogenesis of disease.
Most miRNAs are transcribed by RNA polymerase II, and
their upstream regulatory regions contain canonical core
promoters and enhancers, regulated by transcription factors.
The importance of miRNA biogenesis as a whole in the
immune system is clearly highlighted by the fact that
conditional ablation of Dicer or other miRNA processing
factors resulted in a profound block of both B- and T-cell
development [27–30]. Moreover, deletion or overexpression
of certain individual miRNAs also led to a severe impairment
of the development and/or function of cells of the immune
system [31–38]. Some miRNAs, like miR-146, are expressed
as a family that shares the same seed sequence, but is encoded
by diﬀerent loci in the genome. Indeed, the miR-146a gene
is located on mouse chromosome 11, while miR-146b is
located on chromosome 19 (chromosomes 5 and 10, resp.,
in human). The mature sequences for miR-146a and miR-
146b diﬀer by only two nucleotides. Nevertheless, since
they share the same seed sequence they should in principle
recognize the same targets [39].While in some cell types (like
monocytes) these miRNAs appear to have similar functions
[12], in other cases, like in regulatory T (Treg) cells [10],
only miR-146a, but not miR-146b, was shown to be highly
expressed. While it is still unclear if these two miRNAs
have redundant and/or separate functions, the majority of
the published work focuses mostly on miR-146a, which is
therefore the miRNA we will be mainly referring to in this
paper.
3. MiR-146a in Adaptive Immune Responses
Adaptive immune responses are vital for the eﬃcient eradi-
cation of infectious agents, although dysregulated responses
might also lead to autoimmune and chronic inflammatory
diseases. The development and propagation of an adaptive
immune response specific for an invading pathogen is
a highly orchestrated process that involves the activation
and proliferation of immune cells and their subsequent
migration to sites of inflammation. The first indication that
miRNAs were involved in regulating diﬀerentiation of cells
in the immune system came from a study from Chen and
colleagues that identified miR-181 as a miRNA specifically
expressed in hematopoietic cells [31]. Its ectopic expression
in hematopoietic progenitors led to an increased fraction
of B-lineage cells in both in vitro diﬀerentiation assays and
mousemodels. Following this pioneering work, many studies
identified miRNAs as crucial components of the molecular
circuitry that controls diﬀerentiation and functions of cells
of the immune system.
Upon encounter with the antigen, naı¨ve CD4+ T-
cells give rise to T-cell subsets (Th1, Th2, Th17, Tregs, T
follicular helper and probably others) with functions that are
tailored to their respective roles in host defence [40]. Initial
expression profiling studies identified miRNAs specifically
expressed in diﬀerent T-cell subsets and stages of diﬀeren-
tiation [5–7]. T-cell-specific deletions of Dicer revealed a
requirement for the miRNA pathway in the development
of T cells [27, 29], as well as for diﬀerentiation of eﬀector
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T-cell subsets. Indeed, T cells lacking Dicer showed increased
diﬀerentiation to the Th1 subset with a correspondingly
reduced polarization to Th2 [29]. Adding to the complexity
of gene regulatory networks, proliferating T cells express
genes with shorter 3′ UTRs than those expressed in resting T
cells, making these mRNAs less susceptible to regulation by
miRNAs due to the loss of miRNA binding sites [41]. Finally,
individual miRNAs were also shown to play important
roles in T-cell diﬀerentiation and function. For example,
miR-181a, which is upregulated during T-cell development,
was shown to enhance T-cell receptor (TCR) signalling
strength by directly targeting a number of protein phos-
phatases [32], while mice lacking miR-155 showed an altered
Th1/Th2 polarization with a bias towards Th2, indicating
that miR-155 promotes diﬀerentiation towards Th1 cells
[35].
As for the role of miR-146a in T cells, by analyzing the
expression of miRNAs in highly purified subsets of cells of
the immune system, we showed that miR-146a is one of
the very few miRNAs diﬀerentially expressed between Th1
and Th2 cells in the mouse, suggesting that it might be
involved in fate determination of these cells [5]. Recent work
performed in miR-146a-deficient mice showed an increase
in the percentage of INFγ-producing T-cell subset in the
absence of miR-146a [10]. In human T cells, miR-146a is
expressed at low levels in naı¨ve T lymphocytes while it is
abundantly expressed in memory T cells and it is induced
upon TCR stimulation, consistent with its expression being
dependent on NF-κB induction [12, 13]. Indeed, NF-κB
and c-ETS-binding sites were shown to be required for the
induction of miR-146a transcription in human T cells, and
such induction potentially modulated cell death in these
cells by targeting FADD and by impairing both AP-1 activity
and IL-2 production [13]. Treg cells constitute a specialized
T-cell subset able to maintain immune homeostasis by
limiting the inflammatory responses, and their suppressive
function is indispensable for immune homeostasis and
survival of higher organisms. Recently, Lu and colleagues
reported that miR-146a is among the miRNAs prevalently
expressed in Treg cells and showed that it is critical for
Treg functions. Indeed, deficiency of miR-146a resulted in
increased numbers but impaired function of Treg cells and
as a consequence, breakdown of immunological tolerance
with massive lymphocyte activation, and tissue infiltration in
several organs [10]. The immune-mediated lesions induced
by the lack of miR-146a in Tregs were dependent on INFγ
and Stat1.
4. MiR-146 in Innate Immunity and
Nonimmune Systems
Cells of the innate immune system, such as granulocytes,
natural killer (NK) cells, monocytes, and macrophages,
provide an important first line of defense for the organism
against invading pathogens.MiRNAs have been implicated in
both the development and functions of innate immune cells.
For example, the macrophage inflammatory response to
infection involves the upregulation of several miRNAs, such
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Figure 1: MiR-146a negatively regulates signal transduction path-
ways leading to NF-κB activation. Upon activation of a cell surface
receptor such as TLR4, a molecular cascade including TRAF6
and IRAK1 leads to IκBα phosphorylation and degradation and
to NF-κB activation and nuclear translocation [12, 42]. NF-κB
activation induces transcription of many genes, including pri-miR-
146a. Once translocated to the cytoplasm and loaded onto the
RISC complex, mature miR-146a contributes to attenuate receptor
signaling through the downmodulation of IRAK1 and TRAF6.
as miR-155, miR-146, miR-147, miR-21, and miR-9 [12, 43–
46]. Several studies linked miR-146a expression to NF-κB
signaling within the innate immune system (Figure 1) and
were initiated by a study showing that miR-146a is quickly
induced upon activation of human monocytes [12]. In this
study, miR-146a was found to be inducible upon stimulation
with LPS in a NF-κB-dependent manner, and to target the
TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-
associated kinase 1 (IRAK1) genes. These genes encode two
key adapter molecules downstream of cytokine and Toll-
like receptors (TLR), pointing towards a role for miR-146a
in controlling signaling from these receptors through a
negative feedback regulatory loop involving downregulation
of TRAF6 and IRAK1 [12]. It was also suggested that
miR-146a contributes to the establishment of endotoxin
tolerance in monocytes and to the regulation of TNFα
production [14]. In this context, miR-146a would therefore
act as a tuning mechanism to prevent an overstimulated
inflammatory state. In human Langerhans cells (LCs), miR-
146a was found to be constitutively expressed at high levels,
as compared to interstitial dendritic cells (intDCs) [15].
In these cells, high miR-146a expression was induced by
the transcription factor PU.1 in response to TGF-β1, a key
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signal for epidermal LC diﬀerentiation, and while it did
not influence myelopoiesis or DC subset diﬀerentiation, the
authors suggested that constitutively high miR-146a expres-
sion may represent a novel mechanism to desensitize LCs
to inappropriate TLR signaling at epithelial surfaces through
decreased NF-κB signal strength downstream of the receptor
[15].
Somewhat diﬀerently from the studies mentioned above,
a study performed in human lung alveolar epithelial cells
showed a rapid, time- and concentration-dependent increase
in miR-146a upon stimulation with IL-1β [16]. Such in-
creased miR-146a expression negatively regulated the release
of the proinflammatory chemokines IL-8 and RANTES in
a way that did not seem to involve IRAK1 and TRAF6,
highlighting how the role of miRNAs can be exquisitely
cell type-specific. MiR-146a was also shown to have an
important role in normal epithelial functions: specifically,
miR-146a-mediated downregulation of IRAK1 was suﬃcient
to induce innate immune tolerance and provide protec-
tion from bacteria-induced epithelial damage in neonates
[11].
A molecular cascade involving miR-146a, the miR-146a
negative regulator PLZF, and the miR-146a target CXCR4
was also shown to be active during megakaryopoiesis [17].
This regulatory pathway involved enhanced expression of
PLZF, which in turn inhibited miR-146a transcription. The
resulting downmodulation of miR-146a caused an increase
in CXCR4 expression, which is necessary for megakary-
ocytes diﬀerentiation and maturation. As a result, miR-
146a overexpression, as well as PLZF or CXCR4 silencing,
impaired megakaryocytic proliferation, diﬀerentiation, and
maturation, as well as colony formation [17].
5. MiR-146a and Viruses
Various layers of negative regulators are used by immune cells
to avoid uncontrolled immune responses when facing viral
invasion, and such regulatory mechanisms can also be used
by viruses in order to escape immune surveillance. A role
for miR-146a was discovered in the regulation of vesicular
stomatitis virus (VSV) infection [23]. In macrophages, VSV
infection upregulated miR-146a expression in a RIG-I/NF-
κB-dependent manner. Elevated miR-146a expression led
to negative regulation of the production of VSV-triggered
type I IFN through downregulation of TRAF6, IRAK1, and
IRAK2, thus promoting VSV replication in macrophages
[23]. The authors proposed a model in which VSV infection
is first sensed by RIG-I, which in turn initiates type I IFN
production against VSV infection. At the same time, VSV
infection upregulates miR-146a expression, which inhibits
innate antiviral immune response by impairing RIG-I signal-
ing.
The Epstein-Barr virus (EBV) infects over 90% of the
human population worldwide. EBV infection can result in a
number of malignancies, including Burkitt’s and Hodgkin’s
lymphomas. LMP1 (latent membrane protein 1) is the major
oncoprotein of EBV, able to activate transcription factors
such as NF-κB and AP-1, and thus to manipulate host
cellular processes that regulate cell proliferation, migration,
and apoptosis. Through its ability to activate transcription
factors, LMP1 also induces expression of cellular miRNAs,
most notably miR-146a, which therefore could contribute to
cellular immortalization and tumorigenesis in the context of
EBV infection [24].
6. MiR-146 and Cancer
Cancer is the result of a complex multistep process that
involves the accumulation of sequential alterations in several
genes, including those encoding miRNAs [8, 9]. Since
miRNAs participate in keeping the balance of gene regulatory
networks that determine the fate of a cell, their dysregulation
potentially weakens this balance, thereby contributing to
oncogenesis and cancer progression. Indeed, miRNA profil-
ing has uncovered significantly altered miRNA expression in
many types of cancer [8].
Initial evidences on the possible involvement of miR-
146a in cancer came from a study showing that miR-146a was
upregulated in papillary thyroid carcinoma (PTC) samples
compared with unaﬀected thyroid tissue. Interestingly, a set
of five miRNAs, including miR-221, miR-222, and miR-
146, was suﬃcient to distinguish unequivocally between
PTC and normal thyroid [47]. Similarly to the observations
performed in immunologic settings, overexpression of miR-
146a/b in the highly metastatic human breast cancer cell
line MDA-MB-231 significantly downregulated expression
of IRAK1 and TRAF6, negatively regulating NF-κB activity
[18]. Functionally, this resulted in markedly impaired inva-
sion and migration capacity relative to control cells. These
findings implicated miR-146 not only as a negative regulator
of constitutive NF-κB activity in breast cancer cells, but
also suggested that modulating miR-146 levels might have
therapeutic potential to suppress breast cancer metastases.
Along the same line, miR-146a was among the miRNAs
found upregulated in cervical cancer tissues compared to
normal cervix [19]. When introduced into cell lines, miR-
146a promoted cell proliferation. Although the molecular
mechanism underlying such increased proliferation remains
to be investigated, these observations potentially implicate
miR-146a in cervical carcinogenesis. In another type of
cancer, the hormone-refractory prostate carcinoma (HRPC),
miR-146a levels were diminished compared to androgen-
sensitive noncancerous epithelium [20]. In this context,miR-
146a acted as a tumor suppressor, reducing levels of its
target ROCK1, one of the key kinases involved in HRPC
transformation. Accordingly, forced miR-146a expression
reduced ROCK1 protein levels, cell proliferation, invasion,
and metastasis to human bone marrow endothelial cell
monolayers. Similarly, miR-146a was lower in pancreatic
cancer cells compared with normal human pancreatic
cells [21]. Re-expression of miR146a inhibited the invasive
capacity of pancreatic cancer cells with downregulation
of EGFR (epidermal growth factor receptor) and IRAK-
1. Finally, a recent study showed that the treatment of
bone marrow-derived mesenchymal stem cells (MSCs) with
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diazoxide (DZ) markedly increased the expression of miR-
146a and promoted cell survival. Moreover the down-
regulation of miR-146a expression by antisense inhibitors
eliminated the DZ-induced cytoprotective eﬀects. This result
suggested a critical role of miR-146a in MSC survival
[48].
7. Polymorphisms and Posttranscriptional
Modifications
Polymorphisms aﬀecting miRNA expression, maturation, or
mRNA recognition may also become important determi-
nants for increased tumor risk. Indeed, a genetic variant in
the 3′ UTR of the KIT oncogene was recently described, that
resulted in a mismatch in the seed region of miR-221 and
correlated with increased risk of melanoma [49]. As for miR-
146a, a single nucleotide polymorphism (rs2910164; G/C)
was found on the passenger strand of pre-miR-146a [22]. The
rarer C allele decreased nuclear pri-miR-146a processing,
reducing levels of pre-miR-146a and mature miR-146a and
unblocking expression of its target genes, including TRAF6
and IRAK1. In an association study of PTC patients, the
germ-line GC heterozygous state was associated with an
increased risk of acquiring PTC, while both homozygous
states (GG and CC) were protective. Importantly, this
polymorphism was also found to undergo somatic mutation
in PTC tumor tissue [22], underlying the need for more
studies on polymorphisms, both on the miRNAs themselves
as well as on the binding sites in their targets as, based on
the studies mentioned above, they can clearly contribute to
cancer progression.
Along the same line, point mutations in either a miRNA
or its targets may dramatically alter miRNA expression
and/or functionality, respectively. Even in normal, nondis-
eased conditions, specific adenosine residues of certain
miRNA precursors can be edited by adenosine deaminase
acting on RNA enzymes (ADAR) [50]. The resulting A →
I conversions replace A-U Watson-Crick pairs with I : U
wobble pairs in the double-stranded RNA, altering miRNA
processing. For example, editing of pri-miR-142, expressed
in hematopoietic tissues, resulted in suppression of its
processing by Drosha and consequently in its degradation
[50]. Interestingly, interferons induce the upregulation of
ADAR1 [51], thus raising the possibility that mutations
introduced by ADAR in the pri-miRNAs might lead to
alteration of miRNA expression and/or target recognition
during inflammation [52].
8. miR-146: A Role as Biomarker?
A biomarker is a measurable indicator of a biological state,
either normal or pathological, with or without pharmacolog-
ical treatments [53]. Ideal biomarkers should be detectable
with high sensitivity and specificity, should have high
predictive power, and should be accessible in a noninvasive
manner. The data accumulated on miRNA expression in
tumors demonstrate that miRNAs are indeed promising
candidates to distinguish between diﬀerent tumors and
diﬀerent subtypes of tumors, as well as to predict their
clinical behavior [53]. Large miRNA expression studies have
supported the role of miRNAs as either prognostic and/or
diagnostic markers in various types of cancer (for a detailed
review see [8]). These studies generally showed that the
miRNA profiles reflected the developmental lineage and
the diﬀerentiation status of tumors, and that such miRNA
signatures enabled the tumor samples to be grouped on the
basis of their tissue of origin. Such profiling studies will
become a useful tool to identify miRNA signatures that are
associated with a particular diagnosis or probable outcome
of a disease.
As mentioned above, a good biomarker should also
be easily accessible; the ability to detect clinically relevant
miRNAs in the plasma or serum of patients raises therefore
a lot of interest, particularly since serum miRNAs appear
to exist in a stable and protected form, possibly within
exosome-like particles [53, 54]. Moreover, the levels of
miRNAs in serum were shown to be stable, reproducible,
and consistent among individuals of the same species
[55]. While more studies need to be performed on the
role that miR-146a specifically might have as a biomarker,
there is little doubt that miRNA detection in serum or
PBMCs could provide a convenient and noninvasive measure
for diagnosis and monitoring of many diﬀerent types of
disease.
9. Concluding Remarks
The discovery of miRNAs has revealed a new layer of
regulation of gene expression with a profound impact on
many biological systems. Studies in recent years have shown
that miRNAs have a unique expression profile in cells of the
innate and adaptive immune system and have crucial roles
in the regulation of both cell development and function.
Moreover, it is becoming widely accepted that miRNAs can
function both as oncogenes or tumor suppressors in an
expanding number of tumors and cell types. There is now
increasing evidence to suggest that miR-146a is involved in
the regulation of the adaptive as well as innate immune
response, and that miR-146a can be an important player in
regulating tumor progression. However, more work remains
to be done to fully understand its role and mechanism
of action in normal and pathologic conditions, so that
expression of this miRNA can potentially be exploited as a
new point of entry for therapy. With the identification of a
vast number of miRNAs each carrying a long list of putative
targets, the challenge is now to understand the details of their
biological functions.
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